Vitura Health Limited · ASX:VIT
Vitura Health — FY2023 Earnings Presentation
32 slides from Vitura Health's earnings presentation, Aug 23, 2023
Slide 1: ASX Announcement: Investor Webinar
ASX ANNOUNCEMENT INVESTOR WEBINAR 23 AUGUST 2023 Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to provide details of an investor webinar that will be held at the time and date set out below at which the Company’s 2023 full year financial results will be pres
Slide 2: About Vitura Health Limited (ASX:VIT)
About Vitura Health Limited (ASX:VIT) Vitura Health Limited is listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries, operates the following businesses: ● Burleigh Heads Cannabis - operates the market leading prescriber, patient, pharmacy and supplier online platform, CanView, which sel
Slide 3: Contact and Forward-looking statements
Authorised by Rodney Cocks, Chief Executive Officer and Executive Director Contact Vitura Health Limited Media enquiries Rodney Cocks Tim Fogarty Chief Executive Officer and Executive Director The Civic Partnership 1300 799 491 +61 400 179 075 info@vitura.com.au tim.fogarty@civicpartners.com.au Forw
Slide 4: FY2023 Full Year Financial Report
For personal use only FY2023 FULL YEAR FINANCIAL REPORT INVESTOR PRESENTATION 23 AUGUST 2023 Innovating the delivery of healthcare 1
Slide 5: Investment Highlights and Results – Full Year FY2023
Investment Highlights and Results – Full Year FY2023 Digital health platform company with outstanding growth in FY2023, well positioned for FY2024 growth Market leading, profitable and growing digital health company with a deep moat around the CanView business model Profitable, highly cash generativ
Slide 6: Financial Performance
For personal use only FINANCIAL PERFORMANCE
Slide 7: Financial Highlights – Full Year FY2023
Financial Highlights – Full Year FY2023 A record year on all metrics, with total Revenue of $117m+ and NPAT of nearly $14m Significant, double and triple figure, growth of all major financial metrics in FY2023 compared to FY2022 For personal use only FY2023 Movement FY2022 Revenue $117.34m 75% $66.9
Slide 8: Second fully franked 1.0c dividend declared and DRP
Second fully franked 1.0c dividend declared and DRP Based on Vitura’s record FY2023, the Board has resolved to pay a fully franked dividend for the second consecutive year – rewarding shareholders in a very tangible way For personal use only 1.0 cent 1.0c dividend for every share held Dividend Reinv
Slide 9: Significant revenue growth over the full FY2023
Significant revenue growth over the full FY2023 A record full year, with Revenue growing at a Compound Annual Growth Rate of 132% o H2 FY2023 was focused on development and VIT Revenue Analysis by Half Years rollout of the CanView 2.0 platform, positioning For personal use only H1 FY2021 – H2 FY2023
Slide 10: Financial Overview FY2023 Full Year Results
For personal use only FINANCIAL OVERVIEW FY2023 FULL YEAR RESULTS • PROFIT AND LOSS • BALANCE SHEET • CASHFLOW STATEMENT
Slide 11: Profit and Loss Statement - nearly $14m of NPAT
Profit and Loss Statement - nearly $14m of NPAT Significant operational leverage generated in addition to 129% growth in Net Profit After Tax o Year-on-year revenue growth of 75% driven by significant increase in unit sales For personal use only 30 June 2023 30 June 2022 Continuing operations ($'000
Slide 12: Strong balance sheet with no debt provides flexibility
Strong balance sheet with no debt provides flexibility Increasing net assets and nearly $19m of cash at year end provide organic and inorganic growth options 30 June 2023 30 June 2022 30 June 2023 30 June 2022 Assets ($'000s) ($'000s) Liabilities and equity ($'000s) ($'000s) Current assets Current l
Slide 13: Cash balance increases to record levels at nearly $19m
Cash balance increases to record levels at nearly $19m Cash balance continues to grow even after paying $12.3m in tax and dividends during FY2023 30 June 2023 30 June 2022 Cash flows from operating activities ($'000s) ($'000s) For personal use only Receipts from customers 123,658 69,607 Payments mad
Slide 14: Vision26 - The strategy to deliver sustainable growth
Vision26 - The strategy to deliver sustainable growth Leveraging a successful FY2023, the Board and Executive Leadership Team have developed and implemented Vision26, our 3 year growth strategy with clearly defined strategic priorities for execution For personal use only FY2023 Growth and Operationa
Slide 15: We are a growing, profitable, Australian market leader
We are a growing, profitable, Australian market leader As a market leading digital health platform company with financial strength and a large addressable market, Vitura is well positioned for further growth in FY2024 and beyond with our Vision26 strategy o As a digital health platform business, Vit
Slide 16: Company Overview
For personal use only COMPANY OVERVIEW
Slide 17: The market we operate in is large and growing rapidly
The market we operate in is large and growing rapidly The medicinal cannabis market continues to grow rapidly in Australia, as cannabinoid therapies become mainstreamed for patients, prescribers and pharmacists Estimated Growth Forecast to H1 FY2025 For personal use only (Patient spend at Pharmacy $
Slide 18: We operate at the downstream end of the value chain
We operate at the downstream end of the value chain Vitura Health is focused on the high value, downstream end of the value chain for sustainable long-term growth and profitability – based on our market leading CanView platform For personal use only Cultivation Extraction Manufacturing Finished Prod
Slide 19: What we do – a clear focus on the CanView platform
What we do – a clear focus on the CanView platform Laser focused on the CanView platform, products and our clinic businesses Vitura Health delivers medicinal cannabis prescription, sales and distribution services for prescribers, patients, pharmacies and suppliers throughout Australia via its market
Slide 20: Cortexa Psychedelics JV with PharmAla
Cortexa Psychedelics JV with PharmAla (CSE:MDMA) On 02 May 2023 Vitura Health announced our JV with PharmAla Biotech – Cortexa. Which aims to be a leading supplier of both MDMA and Psilocybin in Australia For personal use only o Vitura Health and Canadian-based PharmAla Biotech o Cortexa will have e
Slide 21: Tech and Distribution JV with Releaf franchise network
Tech and Distribution JV with Releaf franchise network On 16 May 2023 we announced our nationwide JV with Releaf Group – Australia’s Leading National Medical Cannabis Clinical Franchise Network For personal use only o Vitura Health and Australian-based Releaf Group have established o Releaf’s dispen
Slide 22: The CanView platform – an online ecosystem
The CanView platform – an online ecosystem The CanView platform facilitates all aspects of the medicinal cannabis ecosystem for patients, prescribers, pharmacists and suppliers – with clear Network Effects Referred Patient For personal use only Patient books a Prescriber appointment via CanView in p
Slide 23: CanView for Patients
CanView for Patients CanView solves multiple problems for patients that were previously impossible, or very difficult to achieve, without the platform – user friendly interface, intuitive functionality, designed with the patient in mind For personal use only The number of Patients on CanView has gro
Slide 24: CanView for Prescribers
CanView for Prescribers CanView allows prescribers to build their practice, makes prescribing streamlined and underpins their compliance obligations for regulators, including AHPRA and the TGA Quarter on quarter the number of Prescribers For personal use only Cumulative prescriber accounts on CanVie
Slide 25: CanView for Pharmacies
CanView for Pharmacies CanView enables pharmacies to build a dispensing business, and based on feedback from pharmacies it saves them time, delivers on compliance obligations and makes dispensing extremely efficient CanView has onboarded more than For personal use only Cumulative pharmacy accounts o
Slide 26: CanView for Suppliers
CanView for Suppliers For suppliers, CanView generates sales, through prescriber scripts. Moreover, rather than waiting for monthly updates, CanView provides suppliers with real time data, transparency and forecasting insight 39 of the leading brands are onboarded on For personal use only CanView, w
Slide 27: Australia's leading brands have partnered with CanView
Australia’s leading brands have partnered with CanView CanView is trusted by Australia’s leading domestic and international brands to sell and distribute the widest range of medicinal cannabis products available, which currently numbers 39 brands For personal use only Highly rigorous process to sele
Slide 28: The Team – Majority Independent Board and Executive
The Team – Majority Independent Board and Executive Strategy and execution focused We have assembled an experienced, commercially-focused team to execute on the Vision26 strategy and create sustainable shareholder value over the long term. Experienced Independent Board combining deep business develo
Slide 29: Appendices
For personal use only APPENDICES
Slide 30: Appendix – CanView Overview and Benefits
Appendix 1 – CanView Overview and Benefits CanView overview and benefits for prescribers, patients, pharmacists and suppliers in the prescription, sale and distribution of medicinal cannabis products Free to use | The platform is free for all users to register and use For personal use only Complianc
Slide 31: Appendix – Disclaimer applying to this Presentation
Appendix 2 – Disclaimer applying to this Presentation The following disclaimer applies to this presentation (Presentation) You are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this Presentation. This P
Slide 32: Vitura Health Limited
For personal use only VITURA HEALTH LIMITED ASX : VIT www.vitura.com.au info@vitura.com.au 1300 799 491